NASDAQ:GERN - Geron Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $7.00
  • Forecasted Upside: 382.76 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$1.45
▼ -0.01 (-0.68%)

This chart shows the closing price for GERN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Geron Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GERN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GERN

Analyst Price Target is $7.00
▲ +382.76% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Geron in the last 3 months. The average price target is $7.00, with a high forecast of $7.00 and a low forecast of $7.00. The average price target represents a 382.76% upside from the last price of $1.45.

This chart shows the closing price for GERN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 contributing investment analysts is to buy stock in Geron. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/1/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/30/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/28/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/26/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/23/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/23/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/13/2021HC WainwrightReiterated RatingBuy$7.00High
7/26/2021Cantor FitzgeraldReiterated RatingOverweightHigh
4/8/2021HC WainwrightReiterated RatingBuyHigh
2/17/2021B. RileyReiterated RatingBuyHigh
10/14/2020B. RileyReiterated RatingBuyLow
8/26/2020HC WainwrightBoost Price TargetPositive ➝ Buy$4.00 ➝ $7.00High
8/3/2020Stifel NicolausInitiated CoverageBuy$3.00High
6/17/2020Needham & Company LLCReiterated RatingBuy$3.00High
6/1/2020Cantor FitzgeraldBoost Price TargetOverweight$3.00 ➝ $4.00Low
5/29/2020B. RileyBoost Price TargetBuy$3.50 ➝ $4.00High
4/3/2020BTIG ResearchLower Price TargetBuy$4.00 ➝ $3.00High
3/17/2020B. RileyLower Price TargetBuy$4.00 ➝ $3.50High
3/13/2020Needham & Company LLCReiterated RatingBuy$3.00High
12/23/2019Needham & Company LLCReiterated RatingBuy$3.00Low
11/27/2019HC WainwrightReiterated RatingBuy$4.00Medium
11/19/2019B. RileyInitiated CoverageBuy$4.00High
11/7/2019Needham & Company LLCReiterated RatingBuy$3.00Medium
9/3/2019HC WainwrightInitiated CoverageBuy$4.00 ➝ $4.00High
8/15/2019Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$4.00 ➝ $4.00High
6/28/2019B. RileyBoost Price TargetBuy$3.25 ➝ $4.50High
4/9/2019Needham & Company LLCUpgradeHold ➝ Buy$3.00High
2/12/2019BTIG ResearchInitiated CoverageBuy$4.00 ➝ $4.00High
1/31/2019B. RileyUpgradeNeutral ➝ Buy$1.50 ➝ $3.25Low
10/2/2018B. RileyDowngradeBuy ➝ Neutral$5.75 ➝ $1.50High
9/27/2018S&P Equity ResearchLower Price Target$2.32 ➝ $1.80High
7/5/2018FBR & Co.Initiated CoverageBuyHigh
7/5/2018B. RileyInitiated CoverageBuy$5.75High
3/19/2018Piper Jaffray CompaniesReiterated RatingBuy$7.00High
3/18/2018Stifel NicolausBoost Price TargetHold ➝ Hold$2.50 ➝ $4.00High
11/3/2017Needham & Company LLCReiterated RatingHoldN/A
11/3/2017Stifel NicolausReiterated RatingHold$2.50N/A
7/4/2017FBR & Co.Reiterated RatingBuyMedium
4/12/2017Stifel NicolausReiterated RatingHold$2.50Low
4/12/2017Piper Jaffray CompaniesReiterated RatingOverweight$5.00Low
4/6/2017FBR & Co.Reiterated RatingBuyLow
3/2/2017FBR & Co.Set Price TargetBuy$5.00N/A
3/2/2017Needham & Company LLCReiterated RatingHoldN/A
3/2/2017Piper Jaffray CompaniesReiterated RatingOverweight$5.00N/A
(Data available from 10/24/2016 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/28/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/27/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/27/2021
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/26/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/26/2021
  • 1 very positive mentions
  • 19 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/25/2021
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
9/24/2021
  • 1 very positive mentions
  • 15 positive mentions
  • 1 negative mentions
  • 3 very negative mentions
10/24/2021

Current Sentiment

  • 1 very positive mentions
  • 15 positive mentions
  • 1 negative mentions
  • 3 very negative mentions
Geron logo
Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Foster City, CA.
Read More

Today's Range

Now: $1.45
Low: $1.42
High: $1.47

50 Day Range

MA: $1.36
Low: $1.20
High: $1.50

52 Week Range

Now: $1.45
Low: $1.20
High: $2.36

Volume

1,062,396 shs

Average Volume

4,496,780 shs

Market Capitalization

$464.87 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.13

Frequently Asked Questions

What sell-side analysts currently cover shares of Geron?

The following Wall Street research analysts have issued stock ratings on Geron in the last twelve months: B. Riley, Cantor Fitzgerald, HC Wainwright, and Zacks Investment Research.
View the latest analyst ratings for GERN.

What is the current price target for Geron?

1 Wall Street analysts have set twelve-month price targets for Geron in the last year. Their average twelve-month price target is $7.00, suggesting a possible upside of 382.8%. HC Wainwright has the highest price target set, predicting GERN will reach $7.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $7.00 for Geron in the next year.
View the latest price targets for GERN.

What is the current consensus analyst rating for Geron?

Geron currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GERN will outperform the market and that investors should add to their positions of Geron.
View the latest ratings for GERN.

How do I contact Geron's investor relations team?

Geron's physical mailing address is 919 EAST HILLSDALE BOULEVARD SUITE 250, FOSTER CITY CA, 94404. The biopharmaceutical company's listed phone number is (650) 473-7700 and its investor relations email address is [email protected] The official website for Geron is www.geron.com.